Print

Purpose

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female (sex assigned at birth, inclusive of all gender identities). - Age 18 years or above at the time of signing the informed consent. - Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m^2) at screening. - Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.

Exclusion Criteria

  • Known or suspected hypersensitivity to study intervention(s) or related products. - Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening. - Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole [mmol/mol]) as measured by the central laboratory at screening. - History of type 1 or type 2 diabetes mellitus.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
NNC0662-0419 		Participants will receive NNC0662-0419 administered subcutaneously in a dose-escalation manner.
  • Drug: NNC0662-0419
    NNC0662-0419 will be administered subcutaneously.
  • Drug: NNC0662-0419 Placebo
    Placebo matched to NNC0662-0419 will be administered subcutaneously.
Placebo Comparator
NNC0662-0419 placebo 		Participants will receive NNC0662-0419 placebo administered subcutaneously in a dose-escalation manner.
  • Drug: NNC0662-0419 Placebo
    Placebo matched to NNC0662-0419 will be administered subcutaneously.
Experimental
Semaglutide 		Participants will receive semaglutide administered subcutaneously in a dose-escalation manner.
  • Drug: Semaglutide
    Semaglutide will be administered subcutaneously.
  • Drug: Semaglutide placebo
    Placebo matched to semaglutide will be administered subcutaneously.
Placebo Comparator
Semaglutide placebo 		Participants will receive semaglutide placebo administered subcutaneously in a dose-escalation manner.
  • Drug: Semaglutide placebo
    Placebo matched to semaglutide will be administered subcutaneously.

Recruiting Locations

Chambliss Clinical Trials, LLC
Montgomery, Alabama 36106

FDRC
Costa Mesa, California 92627

Los Angeles Institute for Metabolic Research
Los Angeles, California 90015

Encore Medical Research LLC
Hollywood, Florida 33024

South Broward Research LLC
Miramar, Florida 33027

West Orange Endocrinology
Ocoee, Florida 34761

Cedar-Crosse Research Center
Chicago, Illinois 60607

Great Lakes Clinical Trials
Chicago, Illinois 60640

L-MARC Research Center
Louisville, Kentucky 40213

Endo And Metab Cons
Rockville, Maryland 20852

StudyMetrix Research LLC
City of Saint Peters, Missouri 63303

Great Lakes Medical Research
Westfield, New York 14787

KDCILM, LLC & Accellacare US, Inc.
Wilmington, North Carolina 28401

Family Practice Center of Wadsworth Inc.
Wadsworth, Ohio 44281-9236

UPA Ctr Weight and Eating Dis
Philadelphia, Pennsylvania 19104

Clinical Res Collaborative
Cumberland, Rhode Island 02864

Holston Medical Group_Bristol
Bristol, Tennessee 37620

Holston Medical Group
Kingsport, Tennessee 37660

Clinical Research Associates
Nashville, Tennessee 37203

PlanIt Research, PLLC
Houston, Texas 77079

Pinnacle Clinical Research
San Antonio, Texas 78222

National Clin Res Inc.
Richmond, Virginia 23294

Rainier Clin Res Ctr Inc
Renton, Washington 98057

Isis Clinical Res. Ctr P.S.C.
Guaynabo, Puerto Rico 00968

More Details

Status
Recruiting
Sponsor
Novo Nordisk A/S

Study Contact

Novo Nordisk
(+1) 866-867-7178
clinicaltrials@novonordisk.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.